Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma
Open Access
- 5 February 2010
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 49 (5) , 425-438
Abstract
We report an investigation of gene dosage at 9p21.3 and mutations in BRAF and NRAS, as predictors of relapse and histological markers of poor melanoma prognosis. Formalin‐fixed primary melanomas from 74 relapsed and 42 nonrelapsed patients were sequenced for common BRAF and NRAS mutations (N = 71 results) and gene dosage at 9p21.3 including the genes CDKN2A (which encodes CDKN2A and P14ARF), CDKN2B (CDKN2B), and MTAP was measured using multiplexed ligation‐dependant probe amplification (MLPA), (N = 75 results). BRAF/NRAS mutations were detected in 77% of relapsers and 58% of nonrelapsers (Fisher's exact P = 0.17), and did not predict ulceration or mitotic rate. There was no relationship between BRAF/NRAS mutations and gene dosage at 9p21.3. Reduced gene dosage at MTAP showed a borderline association with BRAF mutation (P = 0.04) and reduced gene dosage at the interferon gene cluster was borderline associated with wild type NRAS (P = 0.05). Reduced gene dosage in the CDKN2A regions coding for CDKN2A was associated with an increased risk of relapse (P = 0.03). Reduced gene dosage across 9p21.3 was associated with increased tumor thickness, mitotic rate, and ulceration (P = 0.02, 0.02, and 0.002, respectively), specifically in coding regions impacting on CDKN2B and P14ARF and CDKN2A. Loss at MTAP (P = 0.05) and the interferon gene cluster (P = 0.03) on 9p21 was also associated with tumor ulceration. There was no association between reduced gene dosage at 9p21.3 and subtype or site of tumor. This study presents supportive evidence that CDKN2B, P14ARF, and CDKN2A may all play a tumor suppressor role in melanoma progression.Keywords
This publication has 53 references indexed in Scilit:
- Gene Expression Profiling of Paraffin-Embedded Primary Melanoma Using the DASL Assay Identifies Increased Osteopontin Expression as Predictive of Reduced Relapse-Free SurvivalClinical Cancer Research, 2009
- High resolution analysis of DNA copy-number aberrations of chromosomes 8, 13, and 20 in gastric cancersVirchows Archiv, 2009
- Frequencies of NRAS and BRAF Mutations Increase from the Radial to the Vertical Growth Phase in Cutaneous MelanomaJournal of Investigative Dermatology, 2009
- INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to AtherosclerosisPLOS ONE, 2009
- Environmental risk factors for relapse of melanomaEuropean Journal of Cancer, 2008
- Melanomagenesis: Overcoming the barrier of melanocyte senescenceCell Cycle, 2008
- Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body siteMolecular Oncology, 2007
- A potential predictive marker for response to interferon in malignant melanomaJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2007
- Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanomaJournal of Cancer Research and Clinical Oncology, 2006
- A Population-Based Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2005